JP2006508078A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006508078A5 JP2006508078A5 JP2004543362A JP2004543362A JP2006508078A5 JP 2006508078 A5 JP2006508078 A5 JP 2006508078A5 JP 2004543362 A JP2004543362 A JP 2004543362A JP 2004543362 A JP2004543362 A JP 2004543362A JP 2006508078 A5 JP2006508078 A5 JP 2006508078A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- release formulation
- mixture
- sustained release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 26
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 238000009472 formulation Methods 0.000 claims 9
- 229920002674 hyaluronan Polymers 0.000 claims 9
- 230000002459 sustained Effects 0.000 claims 9
- 229940099552 Hyaluronan Drugs 0.000 claims 6
- KIUKXJAPPMFGSW-MNSSHETKSA-N Hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 claims 6
- 102000003977 fibroblast growth factor 18 Human genes 0.000 claims 5
- 108090000370 fibroblast growth factor 18 Proteins 0.000 claims 5
- 239000000969 carrier Substances 0.000 claims 4
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims 3
- 229920001661 Chitosan Polymers 0.000 claims 3
- 229940072056 alginate Drugs 0.000 claims 3
- 229920000615 alginic acid Polymers 0.000 claims 3
- 235000010443 alginic acid Nutrition 0.000 claims 3
- 239000002260 anti-inflammatory agent Substances 0.000 claims 3
- 229940121363 anti-inflammatory agents Drugs 0.000 claims 3
- 229960003160 hyaluronic acid Drugs 0.000 claims 3
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims 3
- 239000011159 matrix material Substances 0.000 claims 3
- 229920000609 methyl cellulose Polymers 0.000 claims 3
- 239000001923 methylcellulose Substances 0.000 claims 3
- 239000004005 microsphere Substances 0.000 claims 3
- MAKUBRYLFHZREJ-JWBQXVCJSA-M sodium;(2S,3S,4R,5R,6R)-3-[(2S,3R,5S,6R)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylate Chemical compound [Na+].CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@H](O)[C@H]1O MAKUBRYLFHZREJ-JWBQXVCJSA-M 0.000 claims 3
- 239000000243 solution Substances 0.000 claims 3
- WHGYBXFWUBPSRW-FOUAGVGXSA-N β-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims 3
- 210000001612 Chondrocytes Anatomy 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 238000007919 intrasynovial administration Methods 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 206010003246 Arthritis Diseases 0.000 claims 1
- 230000002648 chondrogenic Effects 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
Claims (24)
- 線維芽細胞成長因子18（FGF18）及びヒアルロン酸を含んで成る医薬的に許容できる混合物を含んで成る、軟骨形成ポリペプチドの関節内供給のための組成物。
- 負に荷電されたキャリヤーをさらに含んで成る請求項１記載の組成物。
- 前記キャリヤーが、低分子量ヒアルロナン、高分子量ヒアルロナン、硫酸化されたプロテオグリカン、B−シクロデキストリンテトラデカスルフェート、ヒドロキシアパタイト、アルギネート微小球、キトサン及びメチルセルロースから成る群から選択される請求項２記載の組成物。
- 持効性配合物である請求項１記載の組成物。
- 前記持効性配合物が、溶液、ゲル、ペースト又はパテから成る群から選択されたマトリックスを含んで成る請求項４記載の組成物。
- 前記持効性配合物が、レザバーシステムを含んで成る請求項４記載の組成物。
- 関節内投与の前、FGF18の存在下で培養された軟骨細胞をさらに含んで成る請求項１記載の組成物。
- 抗−炎症薬剤をさらに含んで成る請求項１記載の組成物。
- FGF18及びヒアルロン酸を含んで成る医薬的に許容できる混合物を含んで成る、哺乳類の関節における軟骨細胞増殖のための、滑膜腔内投与用医薬組成物。
- 注射用の請求項９記載の医薬組成物。
- 手術による移植のための請求項９記載の医薬組成物。
- 前記混合物がさらに、低分子量ヒアルロナン、高分子量ヒアルロナン、硫酸化されたプロテオグリカン、B−シクロデキストリンテトラデカスルフェート、ヒドロキシアパタイト、アルギネート微小球、キトサン及びメチルセルロースから成る群から選択された負に荷電されたキャリヤーを含んで成る請求項９記載の医薬組成物。
- 前記混合物が、持効性配合物である請求項９の記載の医薬組成物。
- 前記持効性配合物が、溶液、ゲル、ペースト又はパテから成る群から選択されたマトリックスを含んで成る請求項13記載の医薬組成物。
- 前記持効性配合物が、レザバーシステムを含んで成る請求項13記載の医薬組成物。
- 前記混合物が、抗−炎症薬剤をさらに含んで成る請求項９記載の医薬組成物。
- FGF18及びヒアルロン酸を含んで成る医薬的に許容できる混合物を含んで成る、哺乳類の関節炎を治療するための滑膜腔内投与用医薬組成物。
- 注射用の請求項17記載の医薬組成物。
- 手術による移植のための請求項17記載の医薬組成物。
- 前記混合物がさらに、低分子量ヒアルロナン、高分子量ヒアルロナン、硫酸化されたプロテオグリカン、B−シクロデキストリンテトラデカスルフェート、ヒドロキシアパタイト、アルギネート微小球、キトサン及びメチルセルロースから成る群から選択された負に荷電されたキャリヤーを含んで成る請求項17記載の医薬組成物。
- 前記混合物が、持効性配合物である請求項17の記載の医薬組成物。
- 前記持効性配合物が、溶液、ゲル、ペースト又はパテから成る群から選択されたマトリックスを含んで成る請求項21記載の医薬組成物。
- 前記持効性配合物が、レザバーシステムを含んで成る請求項21記載の医薬組成物。
- 前記混合物が、抗−炎症薬剤をさらに含んで成る請求項17記載の医薬組成物。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41667002P | 2002-10-07 | 2002-10-07 | |
| US60/416,670 | 2002-10-07 | ||
| PCT/US2003/031550 WO2004032849A2 (en) | 2002-10-07 | 2003-10-07 | Methods of administering fgf18 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010286537A Division JP2011079861A (ja) | 2002-10-07 | 2010-12-22 | Ｆｇｆ１８の投与方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006508078A JP2006508078A (ja) | 2006-03-09 |
| JP2006508078A5 true JP2006508078A5 (ja) | 2006-12-07 |
| JP4754823B2 JP4754823B2 (ja) | 2011-08-24 |
Family
ID=32093885
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004543362A Expired - Lifetime JP4754823B2 (ja) | 2002-10-07 | 2003-10-07 | Ｆｇｆ１８の投与方法 |
| JP2010286537A Pending JP2011079861A (ja) | 2002-10-07 | 2010-12-22 | Ｆｇｆ１８の投与方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010286537A Pending JP2011079861A (ja) | 2002-10-07 | 2010-12-22 | Ｆｇｆ１８の投与方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20040136970A1 (ja) |
| EP (1) | EP1551426B1 (ja) |
| JP (2) | JP4754823B2 (ja) |
| AU (1) | AU2003279835B2 (ja) |
| CA (1) | CA2500742C (ja) |
| ES (1) | ES2493840T3 (ja) |
| IL (1) | IL167748A (ja) |
| WO (1) | WO2004032849A2 (ja) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050043234A1 (en) * | 1996-10-16 | 2005-02-24 | Deisher Theresa A. | Novel FGF homologs |
| AU2003279835B2 (en) * | 2002-10-07 | 2009-09-10 | Zymogenetics, Inc. | Methods of administering FGF18 |
| WO2004087055A2 (en) * | 2003-03-27 | 2004-10-14 | Children's Hospital Medical Center | Use of fgf- 18 protein, target proteins and their respective encoding nucleotide sequences to induce cartilage formation |
| CA2592044A1 (en) * | 2004-07-06 | 2006-02-09 | Zymogenetics, Inc. | Pharmaceutical composition comprising fgf18 and il-1 antagonist and method of use |
| US8697139B2 (en) | 2004-09-21 | 2014-04-15 | Frank M. Phillips | Method of intervertebral disc treatment using articular chondrocyte cells |
| DK1828239T3 (da) | 2004-12-10 | 2011-12-19 | Zymogenetics Inc | FGF18-produktion i prokaryote værter |
| CA2633978A1 (en) * | 2005-12-14 | 2007-06-21 | Anika Therapeutics, Inc. | Bioabsorbable implant of hyaluronic acid derivative for treatment of osteochondral and chondral defects |
| US20070196342A1 (en) * | 2005-12-14 | 2007-08-23 | Sadozai Khalid K | Meniscal implant of hyaluronic acid derivatives for treatment of meniscal defects |
| JP4729740B2 (ja) * | 2006-01-11 | 2011-07-20 | 独立行政法人産業技術総合研究所 | 受容体特異性を変化させたミュータント増殖因子およびそれを含有する医薬組成物 |
| CN101505787B (zh) * | 2006-08-25 | 2013-09-04 | 阿雷斯贸易股份有限公司 | 软骨障碍的治疗 |
| AR062522A1 (es) | 2006-08-25 | 2008-11-12 | Ares Trading Sa | Tratamiento de desordenes en cartilagos |
| CN100396340C (zh) * | 2006-09-05 | 2008-06-25 | 四川大学 | 复合型纳米羟基磷灰石/医用高分子材料组织工程支架材料及制备方法 |
| WO2012038953A2 (en) | 2010-09-21 | 2012-03-29 | Hepacore Ltd. | Fgf-18 truncated variants having increased receptor specificity and uses thereof |
| WO2012140650A2 (en) | 2011-04-12 | 2012-10-18 | Hepacore Ltd. | Conjugates of carboxy polysaccharides with fibroblast growth factors and variants thereof |
| TWI527590B (zh) | 2011-06-17 | 2016-04-01 | 艾瑞斯貿易公司 | Ｆｇｆ－１８之凍乾調配物 |
| CN104736723B (zh) | 2012-08-06 | 2017-10-31 | 默克专利有限公司 | 用于预测对fgf‑18化合物的响应性的遗传标记 |
| ITMI20132116A1 (it) * | 2013-12-18 | 2015-06-19 | Apharm Srl | Associazione di glicosamminoglicani e ciclodestrine |
| ES2865723T3 (es) * | 2013-12-24 | 2021-10-15 | Ares Trading Sa | Formulación de FGF-18 en geles de xiloglucano |
| SG11201604972TA (en) * | 2013-12-24 | 2016-07-28 | Ares Trading Sa | Fgf-18 formulation in alginate/collagen hydrogels |
| SG11201606505UA (en) * | 2014-02-20 | 2016-09-29 | Merck Patent Gmbh | Fgf-18 compound dosing regimen |
| PT3107592T (pt) | 2014-02-20 | 2018-12-03 | Merck Patent Gmbh | Implante que compreende fgf-18 |
| CN106232153B (zh) * | 2014-02-20 | 2020-01-17 | 默克专利有限公司 | 用于移植和组织工程手术的fgf-18 |
| CN107383418B (zh) * | 2017-08-18 | 2019-05-17 | 广东宝利兴科技有限公司 | 一种抗紫外线塑料添加剂及其制备方法 |
| RU2020113713A (ru) | 2017-09-21 | 2021-10-21 | Мерк Патент Гмбх | Слитый белок, содержащий молекулу fgf-18 |
| JP2020535436A (ja) | 2017-09-29 | 2020-12-03 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | Ｆｇｆ−１８化合物に対する反応性を予測する代謝バイオマーカー |
| CA3075713A1 (en) | 2017-09-29 | 2019-04-04 | Merck Patent Gmbh | Inflammatory biomarkers for predicting responsiveness to fgf-18 compound |
| SG11202102160VA (en) | 2018-09-10 | 2021-04-29 | Merck Patent Gmbh | Markers useful in enrichment strategies for the treatment of osteoarthritis |
| WO2020161341A1 (en) | 2019-02-08 | 2020-08-13 | Merck Patent Gmbh | Treatment of patients at risk of rapid progression of osteoarthritis |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4530840A (en) * | 1982-07-29 | 1985-07-23 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
| US4636524A (en) * | 1984-12-06 | 1987-01-13 | Biomatrix, Inc. | Cross-linked gels of hyaluronic acid and products containing such gels |
| US5439818A (en) * | 1985-09-12 | 1995-08-08 | Scios Nova Inc. | DNA encoding human recombinant basic fibroblast growth factor |
| US5604293A (en) * | 1985-09-12 | 1997-02-18 | Scios Inc. | Recombinant human basic fibroblast growth factor |
| US5191067A (en) | 1989-04-27 | 1993-03-02 | The Salk Institute For Biological Studies | Fibroblast growth factor conjugates |
| US5576288A (en) | 1989-04-27 | 1996-11-19 | The Salk Institute For Biological Studies | Fibroblast growth factor conjugates |
| US5071655A (en) * | 1990-01-12 | 1991-12-10 | Baylink David J | Pharmaceutical combination for treatment of bone-wasting diseases |
| US5478804A (en) | 1990-09-19 | 1995-12-26 | The Salk Institute For Biological Studies | Treatment of tumorigenic pathophysiological conditions with FGF-cytoxic conjugates |
| US6054122A (en) * | 1990-11-27 | 2000-04-25 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
| DK0565620T3 (da) | 1991-01-03 | 1996-01-22 | Salk Inst For Biological Studi | Mitotoxin til behandling af karbeskadigelse |
| DE4121043A1 (de) * | 1991-06-26 | 1993-01-07 | Merck Patent Gmbh | Knochenersatzmaterial mit fgf |
| US5116753A (en) | 1991-07-30 | 1992-05-26 | The Salk Institute For Biological Studies | Maintenance of pancreatic islets |
| IL103294A0 (en) | 1991-09-30 | 1993-05-13 | Gensia Pharma | Pharmaceutical compositions for preventing tissue damage associated with decreased blood flow |
| US5916772A (en) | 1992-06-16 | 1999-06-29 | Whittier Institute For Diabetes And Endocrinology | Recombinant production of saporin-containing proteins |
| JP3572092B2 (ja) | 1993-09-17 | 2004-09-29 | 帝國製薬株式会社 | 線維芽細胞成長因子含有フィルム製剤 |
| US5656598A (en) * | 1994-03-08 | 1997-08-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Use of fibroblast growth factors to stimulate bone growth |
| US5773252A (en) * | 1995-06-05 | 1998-06-30 | Human Genome Sciences, Inc. | Fibroblast growth factor 15 |
| FR2742662B1 (fr) | 1995-12-21 | 1998-01-23 | Centre Nat Rech Scient | Anticorps anti-idiotypiques du facteur de croissance endotheliale vasculaire et leur utilisation comme medicaments |
| US6200606B1 (en) * | 1996-01-16 | 2001-03-13 | Depuy Orthopaedics, Inc. | Isolation of precursor cells from hematopoietic and nonhematopoietic tissues and their use in vivo bone and cartilage regeneration |
| US6221854B1 (en) * | 1996-03-05 | 2001-04-24 | Orquest, Inc. | Method of promoting bone growth with hyaluronic acid and growth factors |
| WO1998016644A1 (en) * | 1996-10-16 | 1998-04-23 | Zymogenetics, Inc. | Fibroblast growth factor homologs |
| US7135459B2 (en) * | 1996-10-16 | 2006-11-14 | Zymogenetics, Inc. | Methods of use of FGF homologs |
| US6518236B1 (en) * | 1996-10-16 | 2003-02-11 | Zymogenetics, Inc. | FGF homologs |
| US20050043234A1 (en) | 1996-10-16 | 2005-02-24 | Deisher Theresa A. | Novel FGF homologs |
| US5919702A (en) * | 1996-10-23 | 1999-07-06 | Advanced Tissue Science, Inc. | Production of cartilage tissue using cells isolated from Wharton's jelly |
| US6294170B1 (en) | 1997-08-08 | 2001-09-25 | Amgen Inc. | Composition and method for treating inflammatory diseases |
| IL136055A0 (en) | 1997-11-25 | 2001-05-20 | Genentech Inc | Fibroblast growth factor -19 |
| US6171340B1 (en) * | 1998-02-27 | 2001-01-09 | Mcdowell Charles L. | Method and device for regenerating cartilage in articulating joints |
| US20030022170A1 (en) * | 1998-03-06 | 2003-01-30 | Millenium Pharmaceuticals, Inc. | Novel fibroblast growth factors and therapeutic and diagnostic uses therefor |
| AU3076099A (en) | 1998-03-09 | 1999-09-27 | Chiron Corporation | Human fgf gene and gene expression products |
| US6358971B1 (en) | 1998-05-20 | 2002-03-19 | Eli Lilly And Company | Anti-viral compounds |
| JPH11332570A (ja) | 1998-05-27 | 1999-12-07 | Shionogi & Co Ltd | 新規な線維芽細胞成長因子及びそれをコードする遺伝子 |
| WO2000005369A2 (en) | 1998-07-20 | 2000-02-03 | Curagen Corporation | Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis |
| US7067144B2 (en) | 1998-10-20 | 2006-06-27 | Omeros Corporation | Compositions and methods for systemic inhibition of cartilage degradation |
| WO2000056890A1 (en) | 1999-03-19 | 2000-09-28 | Chiron Corporation | Human fgf gene and gene expression products |
| WO2000067775A1 (en) | 1999-05-06 | 2000-11-16 | Human Genome Sciences, Inc. | Fibroblast growth factor 15 |
| US6288043B1 (en) * | 1999-06-18 | 2001-09-11 | Orquest, Inc. | Injectable hyaluronate-sulfated polysaccharide conjugates |
| DE19938736A1 (de) | 1999-08-16 | 2001-02-22 | Bayer Ag | Verfahren zur Herstellung von [Bis-(trifluormethyl)-phenyl]-essigsäuren und deren Alkylestern sowie [Bis-(trifluormethyl)-phenyl]-malonsäure-dialkylester |
| AU1804201A (en) | 1999-12-02 | 2001-06-12 | Zymogenetics Inc. | Methods for targeting cells that express fibroblast growth receptor-3 or-2 |
| US7470665B2 (en) | 1999-12-02 | 2008-12-30 | Zymogenetics, Inc. | Methods for targeting cells that express fibroblast growth receptor-3 or -2 |
| US6677321B1 (en) * | 1999-12-09 | 2004-01-13 | Bruce Levin | Methods and compositions for treatment of inflammatory disease |
| JP2002003398A (ja) * | 2000-04-17 | 2002-01-09 | Ltt Institute Co Ltd | 徐放製剤、その製造法及びワクチン |
| JP2002145797A (ja) | 2000-11-10 | 2002-05-22 | Seishi Yoneda | ヒドロゲルからなる細胞移植療法用材料 |
| IL144446A0 (en) * | 2001-07-19 | 2002-05-23 | Prochon Biotech Ltd | Plasma protein matrices and methods for their preparation |
| US20040203031A1 (en) | 2002-04-03 | 2004-10-14 | University Of Pennsylvania | Methods for determining drug responsiveness |
| CN104178491B (zh) | 2002-09-06 | 2018-07-03 | 安姆根有限公司 | 治疗性人抗-il-1r1单克隆抗体 |
| AU2003279835B2 (en) | 2002-10-07 | 2009-09-10 | Zymogenetics, Inc. | Methods of administering FGF18 |
| US20040229292A1 (en) | 2002-11-26 | 2004-11-18 | Sebastiano Cavallaro | Use of FGF-18 in the diagnosis and treatment of memory disorders |
| WO2004087055A2 (en) | 2003-03-27 | 2004-10-14 | Children's Hospital Medical Center | Use of fgf- 18 protein, target proteins and their respective encoding nucleotide sequences to induce cartilage formation |
| GB0317575D0 (en) * | 2003-07-26 | 2003-08-27 | Rolls Royce Fuel Cell Systems | A reformer module |
| CA2592044A1 (en) | 2004-07-06 | 2006-02-09 | Zymogenetics, Inc. | Pharmaceutical composition comprising fgf18 and il-1 antagonist and method of use |
-
2003
- 2003-10-07 AU AU2003279835A patent/AU2003279835B2/en not_active Expired
- 2003-10-07 WO PCT/US2003/031550 patent/WO2004032849A2/en active Application Filing
- 2003-10-07 CA CA2500742A patent/CA2500742C/en not_active Expired - Lifetime
- 2003-10-07 EP EP03773163.5A patent/EP1551426B1/en not_active Expired - Lifetime
- 2003-10-07 JP JP2004543362A patent/JP4754823B2/ja not_active Expired - Lifetime
- 2003-10-07 ES ES03773163.5T patent/ES2493840T3/es not_active Expired - Lifetime
- 2003-10-07 US US10/680,673 patent/US20040136970A1/en not_active Abandoned
-
2005
- 2005-03-30 IL IL167748A patent/IL167748A/en unknown
-
2008
- 2008-04-16 US US12/104,285 patent/US8507430B2/en active Active
-
2010
- 2010-12-22 JP JP2010286537A patent/JP2011079861A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006508078A5 (ja) | ||
| Zhai et al. | The application of hyaluronic acid in bone regeneration | |
| US11718828B2 (en) | Cartilage gel for cartilage repair, comprising chitosan and chondrocytes | |
| Kim et al. | Porous chitosan scaffold containing microspheres loaded with transforming growth factor-β1: Implications for cartilage tissue engineering | |
| CA2768376C (en) | Methods and compositions for in vitro and in vivo chondrogenesis | |
| Mercier et al. | Poly (lactide-co-glycolide) microspheres as a moldable scaffold for cartilage tissue engineering | |
| Park et al. | Injectable chitosan hyaluronic acid hydrogels for cartilage tissue engineering | |
| US8268950B2 (en) | Glucosamine materials | |
| RU2008144953A (ru) | Культурная среда и фармацевтическая композиция для регенерации хрящевой ткани, способ, применения и относящиеся к ним продукты | |
| IT1317358B1 (it) | Derivati cross-linkati dell'acido ialuronico. | |
| JP2008515832A5 (ja) | ||
| KR20100016299A (ko) | Ｅｐ４ 아고니스트를 함유하여 이루어지는 세포 상해성 ｔ 세포의 활성화제 | |
| US20110097406A1 (en) | Methods and compositions for retaining ecm materials in hydrogels | |
| CN1244429A (zh) | 刺猬蛋白药物组合物及其用途 | |
| US20210015905A1 (en) | Pharmaceutical composition for treating keloid and uses thereof | |
| US10047343B2 (en) | Methods for producing cartilage and bone | |
| Chen et al. | Biomaterials-assisted exosomes therapy in osteoarthritis | |
| US9486496B2 (en) | Anti periodontitis-causing microorganism agent and medical or dental materials using the same | |
| EP1272529A1 (en) | Macroporous chitosan beads and preparation method thereof | |
| Gorji et al. | The effects of fibrin–icariin nanoparticle loaded in poly (lactic-co-glycolic) acid scaffold as a localized delivery system on chondrogenesis of human adipose-derived stem cells | |
| US20070020245A1 (en) | Composition for the treatment of arthrosis/arthritis, especially for treating joints | |
| Şenel et al. | Application of chitosan based scaffolds for drug delivery and tissue engineering in dentistry | |
| Senel et al. | Application of Chitosan Based Scaffolds for Drug Delivery and Tissue | |
| Faikrua et al. | A thermosensitive chitosan/corn starch/β-glycerol phosphate hydrogel containing TGF-β 1 promotes differentiation of MSCs into chondrocyte-like cells | |
| Silva et al. | Drug delivery systems and cartilage tissue engineering scaffolding using marine-derived products |